20.07.2016 - Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.
EBE, the European trade association that represents European biopharmaceutical companies of all sizes, appointed Bravo in June. He had already served as Vice President of EBE for some time.
Bravo, who holds a degree in Business Administration and an MBA (INSEAD), has been CEO of TiGenix since May 2011. He joined the Belgian company in 2005. Prior to that, he held several senior management positions at Sanofi-Aventis, including Vice President for Latin America. He was also general manager for Belgium. Prior to his tenure at Sanofi-Aventis, Bravo spent seven years at SmithKline Beecham in commercial positions both nationally and internationally.http://www.european-biotechnology-news.com/people/bio-people/2016/eduardo-bravo.html